Trial Profile
Phase II Study of Imatinib Mesylate and Docetaxel in Pretreated Patients With Metastatic NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Imatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2016 New trial record